-DOCSTART- -X- O
The -X- _ O
only -X- _ O
severe -X- _ O
acute -X- _ O
respiratory -X- _ O
syndrome -X- _ O
( -X- _ O
SARS -X- _ O
) -X- _ O
vaccine -X- _ O
currently -X- _ O
being -X- _ O
tested -X- _ O
in -X- _ O
clinical -X- _ O
trial -X- _ O
consists -X- _ O
of -X- _ O
inactivated -X- _ B-Intervention
severe -X- _ I-Intervention
acute -X- _ I-Intervention
respiratory -X- _ I-Intervention
syndrome-associate -X- _ I-Intervention
coronavirus -X- _ I-Intervention
( -X- _ I-Intervention
SARS-CoV -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
However -X- _ O
, -X- _ O
limited -X- _ O
information -X- _ O
is -X- _ O
available -X- _ O
about -X- _ O
host -X- _ O
immune -X- _ O
responses -X- _ O
induced -X- _ O
by -X- _ O
the -X- _ O
inactivated -X- _ B-Intervention
SARS -X- _ I-Intervention
vaccine. -X- _ I-Intervention
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
demonstrated -X- _ O
that -X- _ O
SARS-CoV -X- _ B-Intervention
inactivated -X- _ I-Intervention
by -X- _ O
Î²-propiolactone -X- _ O
elicited -X- _ B-Outcome
high -X- _ I-Outcome
titers -X- _ I-Outcome
of -X- _ I-Outcome
antibodies -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
immunized -X- _ I-Outcome
mice -X- _ I-Outcome
and -X- _ I-Outcome
rabbits -X- _ I-Outcome
that -X- _ I-Outcome
recognize -X- _ I-Outcome
the -X- _ I-Outcome
spike -X- _ I-Outcome
( -X- _ I-Outcome
S -X- _ I-Outcome
) -X- _ I-Outcome
protein -X- _ I-Outcome
, -X- _ I-Outcome
especially -X- _ I-Outcome
the -X- _ I-Outcome
receptor-binding -X- _ I-Outcome
domain -X- _ I-Outcome
( -X- _ I-Outcome
RBD -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
S1 -X- _ I-Outcome
region. -X- _ I-Outcome
The -X- _ O
antisera -X- _ O
from -X- _ O
the -X- _ O
immunized -X- _ O
animals -X- _ O
efficiently -X- _ O
bound -X- _ O
to -X- _ O
the -X- _ O
RBD -X- _ O
and -X- _ O
blocked -X- _ O
binding -X- _ O
of -X- _ O
RBD -X- _ O
to -X- _ O
angiotensin-converting -X- _ O
enzyme -X- _ O
2 -X- _ O
, -X- _ O
the -X- _ O
functional -X- _ O
receptor -X- _ O
on -X- _ O
the -X- _ O
susceptible -X- _ O
cells -X- _ O
for -X- _ O
SARS-CoV. -X- _ O
With -X- _ O
a -X- _ O
sensitive -X- _ O
and -X- _ O
quantitative -X- _ O
single-cycle -X- _ O
infection -X- _ O
assay -X- _ O
using -X- _ O
pseudovirus -X- _ O
bearing -X- _ O
the -X- _ O
SARS-CoV -X- _ O
S -X- _ O
protein -X- _ O
, -X- _ O
we -X- _ O
demonstrated -X- _ O
that -X- _ O
mouse -X- _ B-Outcome
and -X- _ I-Outcome
rabbit -X- _ I-Outcome
antisera -X- _ I-Outcome
significantly -X- _ I-Outcome
inhibited -X- _ I-Outcome
S -X- _ I-Outcome
protein-mediated -X- _ I-Outcome
virus -X- _ I-Outcome
entry -X- _ I-Outcome
with -X- _ I-Outcome
mean -X- _ I-Outcome
50 -X- _ I-Outcome
% -X- _ I-Outcome
inhibitory -X- _ I-Outcome
titers -X- _ I-Outcome
of -X- _ I-Outcome
1:7393 -X- _ I-Outcome
and -X- _ I-Outcome
1:2060 -X- _ I-Outcome
, -X- _ I-Outcome
respectively. -X- _ I-Outcome
These -X- _ O
data -X- _ O
suggest -X- _ O
that -X- _ O
the -X- _ O
RBD -X- _ O
of -X- _ O
S -X- _ O
protein -X- _ O
is -X- _ O
a -X- _ O
major -X- _ O
neutralization -X- _ O
determinant -X- _ O
in -X- _ O
the -X- _ O
inactivated -X- _ O
SARS -X- _ O
vaccine -X- _ O
which -X- _ O
can -X- _ O
induce -X- _ O
potent -X- _ O
neutralizing -X- _ O
antibodies -X- _ O
to -X- _ O
block -X- _ O
SARS-CoV -X- _ O
entry. -X- _ O
However -X- _ O
, -X- _ O
caution -X- _ O
should -X- _ O
be -X- _ O
taken -X- _ O
in -X- _ O
using -X- _ O
the -X- _ O
inactivated -X- _ O
SARS-CoV -X- _ O
as -X- _ O
a -X- _ O
vaccine -X- _ O
since -X- _ O
it -X- _ O
may -X- _ O
also -X- _ O
cause -X- _ O
harmful -X- _ O
immune -X- _ O
and -X- _ O
/ -X- _ O
or -X- _ O
inflammatory -X- _ O
responses -X- _ O
. -X- _ O

